ORLANDO-In a phase III study, the investigational GnRH blocker degarelix (Ferring Pharmaceuticals) significantly reduced testosterone levels within 3 days in more than 96% of study patients, Laurence ...

Platinum-based therapy and oral cyclophosphamide as salvage therapy in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients with poor performance status and ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

Testosterone-suppressing treatment with the gonadotropin-releasing hormone (GnRH) antagonist degarelix may reduce dynamic risk factors for sexual offense in men with pedophilic disorder, new research ...

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

A head-to-head study comparing two types of androgen-deprivation therapy (ADT) for the treatment of prostate cancer showed there was no difference in the risk of major adverse cardiovascular events ...

Ferring Pharmaceuticals announced the launch of a phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the US ...

Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

Androgen deprivation therapy (ADT) options for prostate cancer seemed to have a similar impact on the risk of cardiovascular events among people with documented heart disease, according to results ...